Is the affordability debate in Europe changing in the light of COVID19?

Who are the big winners and losers?

From the onset of the COVID19 pandemic, governments turned to the pharmaceutical sector for answers and solutions. Almost a year later, we look at how the present pandemic has reshaped the dynamics within the sector, as well as the power balance between this diverse business sector and European governments. What are the trends for the near future?

We will hear from a venture capitalist investing in pharma, a leading access to medicines advocate, an expert in the science and economics of drug R&D, and the advocacy director of an alternative drug development model.

#A2MDialogues

Panelists

Michelle Childs

Director of Policy Advocacy 

DNDi

Moderated by